Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Core Insights - Anixa Biosciences has received a Notice of Allowance from the USPTO for a key patent application related to its ovarian cancer vaccine technology, which targets Anti-Mullerian Hormone Receptor, Type II (AMHR2) [1][4] - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2] - The allowed claims cover methods of administering an immunogenic composition that elicits an AMHR2-specific immune response [3] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a focus on ovarian cancer immunotherapy and a unique CAR-T technology [4] - The company collaborates with renowned research institutions to develop vaccines for various cancers, including breast, lung, colon, and prostate cancers, targeting "retired" proteins expressed in these malignancies [4] - Anixa's business model emphasizes partnerships at all stages of development, allowing for the exploration of emerging technologies for commercialization [4]